| Title |
Genomic profile of breast cancer: cost–effectiveness analysis from the Spanish National Healthcare System perspective
|
|---|---|
| Published in |
Expert Review of Pharmacoeconomics and Outcomes Research, September 2014
|
| DOI | 10.1586/14737167.2014.957185 |
| Pubmed ID | |
| Authors |
Miguel Ángel Seguí, Carlos Crespo, Javier Cortés, Ana Lluch, Max Brosa, Virginia Becerra, Sebastián Matias Chiavenna, Alfredo Gracia |
| Abstract |
Background: Cost-effectiveness analysis of MammaPrint(®) (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online(®) (online algorithm), 70-gene signature or Oncotype DX(®) (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 and 0.75, respectively, with 70-gene signature. At year 5, the mean cost of 21-gene assay, 70-gene signature and online algorithm was €7100, €6380 and €4580, respectively. 70-gene signature was dominant versus 21-gene assay at any time horizon and would be cost-effective from year 7 versus online algorithm (lifetime: €1457 per quality-adjusted life years gained). Conclusions: 70-gene signature was a dominant strategy over 21-gene assay and was highly cost-effective versus online algorithm. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 1 | 20% |
| Spain | 1 | 20% |
| Unknown | 3 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Iran, Islamic Republic of | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 99 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 20 | 20% |
| Student > Ph. D. Student | 15 | 15% |
| Researcher | 9 | 9% |
| Other | 8 | 8% |
| Student > Doctoral Student | 8 | 8% |
| Other | 26 | 25% |
| Unknown | 16 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 10% |
| Economics, Econometrics and Finance | 9 | 9% |
| Biochemistry, Genetics and Molecular Biology | 8 | 8% |
| Nursing and Health Professions | 7 | 7% |
| Other | 21 | 21% |
| Unknown | 19 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2017.
All research outputs
#6,930,354
of 25,374,917 outputs
Outputs from Expert Review of Pharmacoeconomics and Outcomes Research
#181
of 765 outputs
Outputs of similar age
#65,595
of 255,373 outputs
Outputs of similar age from Expert Review of Pharmacoeconomics and Outcomes Research
#5
of 29 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 765 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,373 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.